# BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)

> **NCT04044001** · PHASE1,PHASE2 · COMPLETED · sponsor: **Michael Hoelscher** · enrollment: 77 (actual)

## Conditions studied

- Pulmonary Tuberculoses
- Other Specified Pulmonary Tuberculosis

## Interventions

- **DRUG:** BTZ-043
- **DRUG:** Rifafour e-275®
- **DRUG:** Probe Drug Cocktail
- **DRUG:** Dolutegravir 50mg Tab

## Key facts

- **NCT ID:** NCT04044001
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2022-03-03
- **Final completion:** 2022-05-31
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2022-08-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04044001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04044001, "BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04044001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*